Capivasertib-Fulvestrant Therapy Increases PFS in HR-Positive Breast Cancer

MONDAY, June 5, 2023 -- For patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therapy results in significantly longer...